20-F: IM Cannabis Corp. Navigates Challenges, Eyes Profitability in 2024 Amidst Strategic Shifts

IM Cannabis Corp. focuses on core markets and cost efficiencies, aiming for profitability in 2024 despite a revenue dip and ongoing market challenges.

Summary

• IM Cannabis Corp. is focusing on the medical cannabis markets in Israel and Germany.
• The company aims to achieve profitability in 2024 through strategic cost management and revenue growth in its core markets.
• Consolidated revenues for 2023 were $48.8 million, a 10% decrease from $54.3 million in 2022, attributed to the Israel-Hamas war and market competition.
• The company is implementing a cost-saving plan that includes discontinuing loss-making activities and reducing payroll.
• A potential reverse merger with Kadimastem, a biotechnology company, is under consideration, which would shift the company's focus from medical cannabis.
• The company is facing challenges, including negative cash flows, market volatility, and regulatory uncertainties.
• The company is working to regain compliance with Nasdaq's minimum share price listing requirement.
• The company is involved in legal proceedings, including a claim in the Ontario Superior Court of Justice and a COVID-19 test kits claim in Germany.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is taking steps to improve its financial performance, it is also facing significant challenges and uncertainties.

Positives

• The company is implementing a cost-saving plan that includes discontinuing loss-making activities and reducing payroll.
• The company is working to regain compliance with Nasdaq's minimum share price listing requirement.

Negatives

• Consolidated revenues for 2023 were $48.8 million, a 10% decrease from $54.3 million in 2022, attributed to the Israel-Hamas war and market competition.
• The company is facing challenges, including negative cash flows, market volatility, and regulatory uncertainties.

Risks

• The company may not be able to secure the funds necessary to implement its strategies.
• Increased competition could materially and adversely affect the business, financial condition and results of operations of the Group.
• The Group is vulnerable to the political, economic, legal, social, regulatory, and military conditions affecting Israel and the Middle East that could have a material adverse effect on the Groups business, results of operations, financial condition and prospects.
• The Company may not be able to continue as a going concern.
• The Company is subject to certain credit exposure.
• The Group may not be able to effectively or successfully address macroeconomic risks and uncertainties or successfully implement operating strategies to mitigate the impact of such risks and uncertainties, which could materially harm the Groups business.
• The Groups facilities are subject to the risk of theft of its product and other security breaches, which could have an adverse effect on the Groups business, financial condition, results of operations and prospects.
• The Group relies on business licenses, permits and approvals and the failure to maintain any of these licenses, permits and approvals could have a material adverse effect on the business, financial condition and results of the operations of the Group.
• Violations of securities laws and breaches of fiduciary duty could result in civil liability, fines, sanctions, or the suspension or revocation of the Groups right to carry on its existing business.
• The Group and its investees operations are subject to various laws, regulations and guidelines, and any potential noncompliance could cause the business, financial condition and results of operations of the Group to be adversely affected.
• The introduction of new tax laws, regulations or rules, or changes to, or differing interpretations of, or application of, existing tax laws, regulations or rules in any of the countries in which the Group invests could result in an increase in the Groups taxes, or other governmental charges, duties or impositions.
• The Groups operations are subject to a variety of laws, regulations, and guidelines, and any changes to such laws, regulations or guidelines could have a material adverse effect on the business, results of operations, financial condition and prospects of the Group.
• Any failure to successfully manage growth and integrate acquired businesses may result in a material adverse effect on the Companys business, financial condition, operating results and prospects.
• Ability to meet target production capacity may result in a material adverse effect on the Groups business, financial condition.
• The Groups operations are subject to environmental and occupational safety laws and regulations, any failure to comply with such environmental and occupational safety laws and regulations could have a material adverse effect on the business, results of operations and financial condition of the Group.
• The failure to secure suppliers or distribution partners could have a material adverse effect on the Groups business, financial condition, results of operations and prospects.
• The Group relies on key business inputs and any failure to secure required supplies and services or to do so on appropriate terms could also have a material adverse effect on the business, financial condition, and operating results of the Group.
• The failure to effectively compete in the Groups markets and introduce new product offerings may cause a material adverse effect on the Groups business, results of operations, financial condition and prospects.
• The Group relies on international third-party transportation services to deliver and receive product-related shipments, which may cause delays and impact the Groups profitability.
• In pursuit of new opportunities in the cannabis industry, the Company may fail to select appropriate investment candidates and negotiate acceptable arrangements, which could adversely affect the Companys ability to enter into new investments.
• Strategic alliances that the Group enters into could present unforeseen integration obstacles or costs, may not enhance the Groups business, and may involve risks that could adversely affect the Group.
• Unfavorable divestments could have a material adverse effect on the Company.
• The Company relies upon the ability, judgment, discretion and good faith of key personnel, and the inability to attract, develop, motivate and retain highly qualified employees could have a material adverse effect on the Companys business, financial condition and results of operations.
• The Group relies on international advisors and consultants for its operations in foreign countries.
• Foreign market participation subjects the Group to the global capital markets and government authorities, which could have a material adverse effect on the Groups business, financial condition and results of operations.
• Future acquisitions or dispositions could result in the failure to realize anticipated benefits of such transactions.
• Foreign expansion efforts and operations could subject the Group to additional business risks, and the potential failure of the Groups operating infrastructure to support such expansions could result in operational failures and regulatory fines or sanctions.
• The Company has no U.S. operations.
• The Company is subject to risks inherent in the agricultural business.
• Illegal market competition in the cannabis market could have a material adverse effect on Groups business, operating results and prospects.
• Consumer perception of the Groups products can be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of medical cannabis products.
• Groups products could have certain side effects if not taken as directed or if taken by an end user that has certain known or unknown medical conditions.
• Reputational risk to third parties could result in the failure to establish or maintain business relationships.
• The failure of the Groups IT systems or a component of IT systems could, depending on the nature of any such failure, adversely impact the Groups financial condition, operating results and reputation.
• Cybersecurity risks could adversely impact the Groups financial condition, operating results and reputation.
• Any theft of personal information about the Groups patients and customers or privacy breach could have a material adverse effect on the Groups business, financial condition and results of operations.
• The price of cannabis products is affected by numerous factors beyond the Groups control.
• Fraudulent or illegal activity may cause a material adverse effect on the Groups business, reputation, financial condition, and results of operations.
• Corruption and anti-bribery law violations could cause severe penalties and other consequences that may have a material adverse effect on its business, reputation, financial condition and results of operations.
• The Group uses intellectual property protections such as trademarks, trade secrets and contractual confidentiality obligations in order to protect its products, brands and technologies.
• Company is subject to the rules and regulations of the Canadian Stock Exchange and the Nasdaq Capital Market.
• Significant sales of the Companys listed securities could depress the market price of the Companys securities and impair the Companys ability to raise capital.
• The Company may issue additional securities in the future, which may dilute a shareholders holdings in the Company.
• The Companys cash flows and ability to pursue future business and expansion opportunities are dependent on the earnings of its subsidiaries and investees and the distribution of those earnings to the Company.
• The Company has not paid any dividends on the outstanding Common Shares and maintains no current intention to declare dividends in the foreseeable future.
• The market price of the Companys Common Shares and warrants may fluctuate, which may have a material adverse effect on the Companys operations, financial condition and operating results.
• The failure to design, develop or maintain effective internal controls may affect the Companys ability to prevent fraud, detect material misstatements, and fulfill reporting obligations.
• The possible lack of liquidity of securities may cause difficulty for security holders to re-sell securities at desired prices.
• The Groups debtors may default on payments owed to the Group.
• The Group is subject to the inherent liquidity risk that it will not be able to pay its financial obligations as they become due.
• There is a risk that losses will be incurred by the Group if there is an adverse shift in exchange rates or increases in prevailing interest rates.
• The Company is dependent upon the global capital markets to raise capital by equity or debt financing.
• Increased levels of volatility and market turmoil can adversely impact the Groups operations and the value, and the price of the Common Shares and/or Warrants could be adversely affected.
• A judgment against any member of the Group in excess of available insurance coverage could have a material adverse effect on the Group in terms of damages awarded and negatively impact the reputation of the Group.
• The insurance purchased by the Group cannot cover all risks that the Group is exposed to, and any uninsured amounts of liabilities incurred by member(s) of the Group may be paid directly by such members.
• The Groups products face an inherent risk of exposure to product liability claims, regulatory action and litigation if such products are alleged to have caused significant loss or injury.
• Members and/or representatives of the Group are or may become parties to litigation from time to time in the ordinary course of business that could adversely affect the Groups business.
• A failure of the Groups quality control systems could result in significant costs incurred in replacing, destroying or repurposing defective inventory, providing replacement products to its customers or recalling such products.
• If the Groups products are recalled due to an alleged product defect or for any other reason, the Group could be required to incur the unexpected expense of the recall and any legal proceedings that might arise in connection with the recall and may lose a significant amount of sales.
• Inaccuracies in forecasting market conditions could have a material adverse effect on the Groups business, financial condition and results of operations.
• The Groups business may be negatively impacted by catastrophic events, natural disasters, severe weather and disease.
• The Group is subject to a variety of anti-money laundering laws and regulations.
• The Group may not be able to effectively enforce security over underlying assets, which could have a material adverse effect on the Group.
• The Company, its officers and directors may be subject to various potential conflicts of interest, which could adversely affect Company operations.
• The Company is a foreign private issuer under United States Securities Laws.
• Loss of foreign private issuer status under United States securities laws could increase the Companys regulatory and compliance costs.
• Loss of emerging growth company status under United States securities laws could increase the Companys regulatory and compliance costs.
• The Group operates in multiple jurisdictions and is subject to currency fluctuations.
• The Companys shareholding in other entities is subject to price fluctuations.
• Judicial and legislative reforms in Israel.
• CCAA Proceedings.

Future Outlook

The company aims to achieve profitability in 2024 through strategic cost management and revenue growth in its core markets.

Industry Context

The medical cannabis industry is competitive, with companies competing on a regional basis. The industry is undergoing rapid growth and substantial change, which has resulted in an increase in competitors, consolidation and formation of strategic relationships.

Management Changes

Legal Proceedings

• The company is involved in legal proceedings, including a claim in the Ontario Superior Court of Justice and a COVID-19 test kits claim in Germany.

Related Party Transactions

• The Stalking Horse Purchase Agreement constituted a related party transaction as L5 Capital is an entity controlled by Marc Lustig, who was a director of Trichome and the Executive Chairman of the Board.
• On January 16, 2023, the Company closed of the first tranche of the Concurrent Offering comprised of an aggregate of 1,159,999 Units for aggregate gross proceeds of US$1,500. The Concurrent Offering was led by insiders of the Company.
• On January 20, 2023, the Company closed the second tranche of the LIFE Offering comprised of 102,152 Life Units for an aggregate subscription price of approximately US$128. The second tranche of the LIFE Offering was comprised of a single subscription by the Executive Chairman of the Company whose subscription price was satisfied by the settlement of approximately US$128 in debt owed by the Company to him for certain consulting services previously rendered to the Company.
• On February 16, 2023, the Company closed the fifth and final tranche of the LIFE Offering. Marc Lustig, the Executive Chairman of the Company subscribed for 29,548 Life Units in the fifth tranche at an aggregate subscription price of US$37. Marc Lustigs subscription price was satisfied by the settlement of US$37 in debt owed by the Company to the director for certain consulting services previously rendered by the director to the Company.
• Pursuant to the consulting agreement between the Company and L5 Capital, the Company issued 50,414 Common Shares as a result of the vested RSUs according to the agreed vesting schedule. The Common Shares were issued on May 5, 2023. In July 24, 2023, an additional 4,585 Common Shares were issued as a result of the vested RSUs according to the agreed vesting schedule.
• On October 12, 2023, Oren Shuster, the CEO loaned an amount of NIS 500 (approximately $170) to IMC Holdings.

Stakeholder Impact

• The company is taking steps to improve its financial performance, which could benefit shareholders.
• The company is facing challenges, including negative cash flows and market volatility, which could negatively impact shareholders.

Next Steps

• The company plans to pursue available options to regain compliance with Nasdaq's minimum share price listing requirement, including potentially pursuing a reverse stock split.
• The parties are committed to seeking a successful completion of the Proposed Transaction with Kadimastem as soon as practicable.

Key Dates

Keywords

medical cannabis, profitability, financial results, Israel, Germany, Kadimastem, reverse merger, legalization, revenue, expenses, regulations, licenses, risk factors, financial statements, operations